Albert DaCosta

Chairman, President, and Chief Executive Officer at FNA

Board

Since 2012

Age

50 years

Education

Earned a B.S. in Chemical Engineering with a minor in Business from the University of Florida.

Tenure

Joined FNA in 2012 as a co-founder and has served as Chairman, President, and Chief Executive Officer, in addition to being a Board member since that year.

Also at FNA

Kristina Wright

Interim Chief Financial Officer

Chadi Chahine

Chief Financial Officer and Executive Vice President of Supply Chain Operations

Drew Hill

Executive Vice President of Research and Development

About

Albert DaCosta is the co-founder and key executive driving FNA, having played a critical role in its formation and sustained growth since 2012. With over 18 years of experience in the foot and ankle industry, he laid the foundation for FNA’s evolution by leveraging his deep industry expertise and strategic vision.

Educated in Chemical Engineering with a minor in Business from the University of Florida, he has applied his technical knowledge and leadership skills to innovate within the medical device field. His early career included significant roles ranging from a sales representative to a distributor and even founding his own ventures, which helped shape his capabilities as a business leader.

Throughout his professional journey, his contributions have been instrumental in establishing a strong corporate culture and driving innovation, ensuring that FNA remains competitive in the highly specialized healthcare sector. His leadership not only underscores his dedication to excellence in this niche industry but also reflects his broader commitment to advancing healthcare solutions.

$FNA Performance Under Albert DaCosta

Past Roles

Organization	Role	Date Range	Details
Pioneer Surgical and Biomet Sports Medicine	Distributor	2009-2010	Worked as distributor for these companies
Wright Medical	Director of Biologics & Extremities	N/A [N/A]	Served in a director role
Body Beautiful Laser Centers	President & Founder	2006	Based in South Florida
Non-Invasive Solutions	President	2005	N/A [N/A]
Linvatec	Sales Representative	2003	N/A [N/A]

Fixed Compensation

Data from FY 2023

Component Name	Amount (USD)	Payment Schedule	Additional Details
Salary	$700,769	Annual	Fixed base salary
401(k) Plan Contribution	$9,990	Annual	401(k) contribution
Executive Level Insurance Benefits (Medical, Life, and Disability)	$21,857	Annual	Group insurance benefits

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan

Metric Description	Value	Details/Conditions
Target Annual Cash Bonus Opportunity	100% of base salary	Implies bonus target equals annualized base salary
Threshold Payout	$355,000	Achieved at 50% of target if revenue objective met at threshold
Target Payout	$710,000	Base target payout
Maximum Payout	$1,420,000	Capped at 200% of target with maximum revenue and adjusted free cash flow achievement
Actual Bonus Award	$667,400	Represents 94% of the target payout based on 2023 revenue achievement of $216.4 million
Performance Metrics	Revenue and Adjusted Free Cash Flow	Revenue threshold achieved partially; adjusted free cash flow goals not achieved
Evaluation Period	2023	Based on the 2023 Bonus Plan
Vesting Schedule	N/A (cash-based)	Cash incentive; no vesting required
Grant Date for Plan-Based Awards	February 28, 2023	Establishes the period of performance measurement

Stock Awards (Restricted Stock Units - RSUs)

Metric Description	Value	Details/Conditions
Number of RSUs	102,374	Granted in 2023
Grant Date	February 28, 2023	Specific grant date provided
Grant Date Fair Value	$1,832,495	Total fair value of the restricted stock units granted
Vesting Schedule	25% each anniversary	25% vest on the first anniversary; remaining vest at 25% per year over the subsequent three years
Performance Conditions	None	Awards are time-based with no performance metrics attached
Grant Date Stock Price	N/A	Stock price on grant date not provided